The State of PE-Backed Orthopedic MSOs

Key Takeaways

• Entry multiples 12x EBITDA now outpaced by debt service costs
• Rising SOFR rates added $12‑15M annual interest on $300M debt
• Physician common equity often left narrow or impaired
• Exit market stalled: 13 PPM deals in 2024 vs ~100 earlier
• ASC facility fees now fund debt, not surgeon upside

Pulse Analysis

The private‑equity surge in orthopedics was fueled by a perfect storm: fragmented practices, high‑volume procedures, and a regulatory shift that moved total joint replacements from hospitals to ambulatory surgery centers. Low‑cost capital allowed firms to pay 6‑10× EBITDA at acquisition and project 12‑14× multiples at exit, banking on ASC facility fees that could dwarf surgeon professional fees. This model seemed airtight until macro‑economic tides turned.

Since mid‑2022, the Federal Reserve’s rate hikes have pushed the Secured Overnight Financing Rate (SOFR) above 5%, inflating borrowing costs for platforms that loaded $300‑plus million of floating‑rate debt. The added $12‑15 million in annual interest erodes EBITDA, while Medicare and commercial reimbursement for knee and hip replacements continues to compress. Consequently, physician common equity—often a modest rollover stake—has become narrow or even impaired, and the anticipated “second bite” liquidity event looks increasingly doubtful.

Looking ahead, the orthopedic MSO landscape faces a crossroads. Continued hold periods and scarce exits suggest that traditional PE timelines are misaligned with the multi‑year integration needed for true operational efficiencies, such as centralized revenue cycle management and value‑based care contracts. Platforms may need to explore strategic buyers like health‑system operators or consider hybrid recapitalizations to extend runway, while surgeons must scrutinize deal structures, prioritize cash at close, and retain control over ASC revenue streams. The sector’s evolution will hinge on balancing capital‑intensive growth with sustainable, physician‑aligned economics.